T/CACM 1383-2022 Active Group standards

T/CACM 1383-2022 Non-alcoholic fatty liver disease: Chinese medicine guidelines for diagnosis and treatment

T/CACM 1383-2022 Non-alcoholic fatty liver disease: Chinese medicine guidelines for diagnosis and treatment

Publish Date: 2022-04-06 Implement Date: 2022-04-06 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us
Price: $ 20.00
Download

Basic Information

Standard Code: T/CACM 1383-2022
Standard Type: Group standards
Standard Status: Active
is_force_gb: no
CCS Name: -
ICS Name: Integrated medical science and healthcare devices
Publish Date: 2022-04-06
Implement Date: 2022-04-06
Pages: 24 pages

Scope

Scope: This document defines the terms and definitions of non-alcoholic fatty liver inflammation, and clarifies its diagnosis, traditional Chinese medicine differentiation, treatment, efficacy evaluation, and preventive care. This document is applicable to the clinical diagnosis and treatment of non-alcoholic fatty liver inflammation in patients aged 16 and above; it is suitable for clinicians in relevant departments of general hospitals, including traditional Chinese medicine departments, integrated traditional and Western medicine departments, liver disease departments, and digestive departments in traditional Chinese medicine hospitals, as well as primary-level hospitals. Main technical content: Foreword II Introduction III 1  Scope 12  Normative reference documents 13  Terms and definitions 14  Diagnosis 24.1 Western medical diagnosis 24.2 Traditional Chinese medicine diagnosis 35  Traditional Chinese medicine differentiation 35.1 Symptoms 35.2 Symptom diagnosis 36  Treatment 36.1 Treatment principles 36.2 Scientific dietary principles 36.3 Exercise guidance principles 46.4 Differentiated prescriptions and medicines 46.5 Prescription and medicine research recommendations 46.6 Traditional Chinese medicines 56.7 External traditional Chinese medicine therapies 67  Preventive care 67.1 Changing unhealthy behaviors 67.2 Controlling comorbidities 77.3 Regular checkups 7 Appendix A (informative) Efficacy evaluation 8 Appendix B (informative) Composition of the drafting group 10 Appendix C (informative) Guide development workflow 12 Appendix D (informative) Evidence grading in the guide 13 Appendix E (informative) Explanation of recommendation strength 18 References 19

Development Information

Pages: 24 pages

Related Standards

Contact Us